Format
Items per page

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Multiple myeloma

Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). [from OMIM]

MedGen UID:
10122
Concept ID:
C0026764
Neoplastic Process
2.

Multiple myeloma

MedGen UID:
505979
Concept ID:
CN005898
Finding
3.

Multiple congenital anomalies

MedGen UID:
7806
Concept ID:
C0000772
Congenital Abnormality
4.

Poor prognosis

MedGen UID:
548766
Concept ID:
C0278252
Finding
5.

Risk factor

An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, on the basis of epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. [from MeSH]

MedGen UID:
48477
Concept ID:
C0035648
Finding
6.

Recurrence

The return of a sign, symptom, or disease after a remission. [from MeSH]

MedGen UID:
416712
Concept ID:
C2825055
Pathologic Function
7.

Plasma Cell Neoplasm

A clonal proliferation of immunoglobulin-secreting plasma cells. This category includes plasma cell myeloma, plasma cell leukemia, plasmacytoma, monoclonal immunoglobulin deposition disease, and monoclonal gammopathy of undetermined significance. [from NCI]

MedGen UID:
368758
Concept ID:
C1959632
Neoplastic Process
8.

Growth substance

Signal molecules that are involved in the control of cell growth and differentiation. [from MeSH]

MedGen UID:
315661
Concept ID:
C1812630
Biologically Active Substance; Pharmacologic Substance
9.

Angiogenesis Modulating Agents

Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents. [from MeSH]

MedGen UID:
263447
Concept ID:
C1257849
Pharmacologic Substance
10.

Monoclonal Gammopathy

An abnormal laboratory test result indicating the presence of monoclonal immunoglobulins in the blood or urine. [from NCI]

MedGen UID:
210153
Concept ID:
C1136085
Neoplastic Process
11.

Vascular hemostatic disease

Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS. [from MeSH]

MedGen UID:
154721
Concept ID:
C0600502
Disease or Syndrome
12.

Angiogenesis inhibitor

Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. [from MeSH]

MedGen UID:
154540
Concept ID:
C0596087
Biologically Active Substance; Pharmacologic Substance
13.

Thalomid

MedGen UID:
148974
Concept ID:
C0723668
Organic Chemical; Pharmacologic Substance
14.

Sedoval

MedGen UID:
147533
Concept ID:
C0729007
Hazardous or Poisonous Substance; Organic Chemical; Pharmacologic Substance
15.

Sequence Deletion

Deletion of sequences of nucleic acids from the genetic material of an individual. [from MeSH]

MedGen UID:
102460
Concept ID:
C0162773
Cell or Molecular Dysfunction
16.

Growth Inhibitors

Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS). [from MeSH]

MedGen UID:
42306
Concept ID:
C0018282
Biologically Active Substance; Pharmacologic Substance
17.

Vascular disorder

MedGen UID:
22621
Concept ID:
C0042373
Disease or Syndrome
18.

Thalidomide

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. [from MeSH]

MedGen UID:
11761
Concept ID:
C0039736
Hazardous or Poisonous Substance; Organic Chemical; Pharmacologic Substance
19.

Paraproteinemia

A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. [from MeSH]

MedGen UID:
10577
Concept ID:
C0030489
Disease or Syndrome
20.

Immunoproliferative disorder

Disorders characterized by abnormal proliferation of primary cells of the immune system or by excessive production of immunoglobulins. [from MeSH]

MedGen UID:
7038
Concept ID:
C0021070
Neoplastic Process
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center